New therapeutic approaches to autoimmune diseases;Nouvelles approches thérapeutiques des maladies autoimmunes

Presse Medicale

Volumn 35, Issue 4 II, 2006, Pages 709-713

  Amoura, Zahir ^a   Piette, Jean Charles ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ABETIMUS; ANTICOAGULANT AGENT; BELIMUMAB; BG 9588; CD40 LIGAND MONOCLONAL ANTIBODY; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 12 ANTIBODY; LJP 1082; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD3; NATALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; B CELL ACTIVATING FACTOR; BLOCKING ANTIBODY; CD20 ANTIGEN; CD28 ANTIGEN; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; IMMUNOLOGIC FACTOR; MEMBRANE PROTEIN; TNFSF13B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; LYMPHOMA; NONHUMAN; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RHEUMATOID ARTHRITIS; SCLEROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; THROMBOEMBOLISM; THROMBOSIS; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METHODOLOGY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIGENS, CD28; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL ADHESION MOLECULES; CHEMOKINES; CROHN DISEASE; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33646930362     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0755-4982(06)74667-X     Document Type: Article

References (30)

1. Looney, RJ, Anolik J, Sanz I. B cells as therapeutic targets for rheumatic diseases. Curr Opin Rheumatol. 2004; 16: 180-5.
2. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum. 2003; 48: 1484-92.
3. Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to bedside: ways to improve rituximab efficacy. Blood. 2004; 104: 2635-42.
4. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350: 2572-81.
5. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002; 46: 2673-7.
6. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood. 2002; 99: 3872-3.
7. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001; 358: 1511-3.
8. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood. 2003; 101: 3827-34.
9. Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology. 1999; 52: 1701-4.
10. Specks U, Fervenza FC, McDonald TJ, Hogan MC. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum. 2001; 44: 2836-40.
11. Ramanujam M, Davidson A. The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther. 2004; 6: 197-202.
12. Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes BEyS bioactivities. Arthritis Rheum. 2003; 48: 3253-65.
13. Furie R, Stohl W, Ginzler E, Becker M, Mishra N, Chatham W et al. Safety, pharmacokinetic and pharmacodynamic results of a Phase 1 single and double dose-escalation study of LymphoStat-B (human monoclonal antibody to BLyS) in SLE patients. 67th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals. October 26, 2003. Abstract 922.
14. Alarcon-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2003; 48: 442-54.
15. Merrill JT. LJP 1082: a toleragen for Hughes syndrome. Lupus. 2004; 13: 335-8.
16. Lajaunias F, Ida A, Kikuchi S, Fossati-Jimack L, Martinez-Soria E, Moll T et al. Differential control of CD22 ligand expression on B and T lymphocytes and enhanced expression in murine systemic lupus. Arthritis Rheum. 2003; 48: 1612-21.
17. Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4lg. Science. 1994; 265: 1225-7.
18. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P et al. Costimulatory blockade in patients with rheumatoid arthritis. A pilot, dose-finding, double blind, placebo-controlled clinical trial evaluating CTLA-4lg and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002; 46: 1470-9.
19. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S et al. Treatment of Rheumatoid Arthritis by selective inhibition of T-cell activation with fusion protein CTLA4lg. N Engl J Med. 2003; 349: 1907-15.
20. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003; 48: 719-27.
21. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. Nat Med. 2000; 6: 114.
22. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med. 2005; 352: 2598-608.
23. Bisikirska B, Colgan J, Luban J, Bluestone JA, Herald KC. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest. 2005; 115: 2904-13.
24. Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004; 351: 2069-79.
25. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum. 2000; 43: 1790-800.
26. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P et al. Natalizumab for active Crohn's disease. N Engl J Med. 2003; 348: 24-32.
27. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice JP, Libonati MA et al.; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003; 348: 15-23.
28. Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen conseguences. N Engl J Med. 2005; 353: 414-6.
29. Van Assche G, Van Ranst M, Sciot R, Dubois B, Vermeire S, Noman M et al. Progressive multi-focal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med. 2005; 353: 362-8.
30. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005; 353: 369-74.